Difference between revisions of "Ropeginterferon alfa-2b (Besremi)"
m |
m |
||
Line 20: | Line 20: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
+ | [[Category:Pegylated medications]] | ||
[[Category:Interferon alfas]] | [[Category:Interferon alfas]] |
Revision as of 11:33, 23 September 2023
General information
Class/mechanism per NCI Drug Dictionary: A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b) protein, in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon subcutaneous administration, IFN-a2b binds to specific interferon cell-surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs); the protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a predominant (90%) positional isomer which allows for further increases in stability and a longer half-life than previous PEG conjugates.
Route: SC
Extravasation: n/a
Diseases for which it is used
History of changes in FDA indication
- 2021-11-12: Initial approval for adults with polycythemia vera. (Based on PEGINVERA)
History of changes in EMA indication
- 2019-02-15: Initial authorization
History of changes in PMDA indication
- 2023-03-27: Initial approval
Also known as
- Code name: AOP-2014
- Generic name: ropeginterferon alfa-2b-njft
- Brand name: Besremi